Supercharge Your Innovation With Domain-Expert AI Agents!

Novel nitrocatechol derivatives having selectin ligand activity

A technology for selecting proteins and drugs, applied in the field of compounds for in vitro and in vivo processes, capable of solving problems such as low potency and high molecular weight

Inactive Publication Date: 2013-04-24
REVOTAR BIOPHARMACEUTICALS AG
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

To date, almost all promising selectin antagonists have not been able to become commercially available drugs, mainly because of low potency and / or high molecular weight, which defects in the absorption-distribution-metabolism-excretion (ADME) behavior of said compounds cause Various issues, thus causing problems in the oral bioavailability required for the treatment of most inflammatory diseases such as rheumatoid arthritis, septic shock, atherosclerosis, reperfusion injury and many others

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel nitrocatechol derivatives having selectin ligand activity
  • Novel nitrocatechol derivatives having selectin ligand activity
  • Novel nitrocatechol derivatives having selectin ligand activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment A

[0215] Preparation of [5-(2-amino-phenyl)-thiophen-2-yl]-acetic acid methyl ester (87)

[0216] Reaction scheme 11

[0217]

[0218] Step 1: (The following reactions were carried out under anhydrous nitrogen atmosphere) Thiophen-2-yl-acetic acid methyl ester (85) (2.0 g, 12.8 mmol) was dissolved in anhydrous chloroform (9.0 mL) and glacial acetic acid (9.0 mL) , N-bromosuccinimide (2.3 g, 13.0 mmol) was added in portions and the mixture was stirred at room temperature for 3 days, water was added to the reaction mixture, the layers were separated, the aqueous layer was extracted with dichloromethane, and the combined organic The layer was washed several times with 1M NaOH aqueous solution and water, then once with brine and washed with Na 2 SO 4 Drying and purification of the crude product by preparative radial chromatography (CyH / EtOAc 5+1] afforded (5-bromo-thiophen-2-yl)-acetic acid methyl ester (86) as a yellow oil (2.46 g, 81 %), which was used without further purifi...

Embodiment B

[0221] Preparation of 5-(2-amino-phenyl)-thiophene-2-carboxylic acid methyl ester (90)

[0222] Scheme 12

[0223]

[0224] Step 1: LE23 5-Bromo-thiophene-2-carboxylic acid (88) (1.50 g, 7.24 mmol) was dissolved in methanol (10 mL) and concentrated sulfuric acid (0.39 mL, 7.24 mmol) was added. The reaction mixture was stirred at 75 °C for 20 hours, the mixture was cooled to room temperature, the solvent was removed under reduced pressure, and the residue was dissolved in EtOAc, the organic layer was washed with 5% Na 2 CO 3 The aqueous solution was washed 3 times and the combined aqueous layers were extracted with EtOAc. The combined organic layers were washed with brine and washed with Na 2 SO 4 After drying, the solvent was removed under reduced pressure and the residue was dried under oil pump vacuum without further purification to afford the ester (89) as a white solid (1.48 g, 92%). 1 H NMR (400MHz, CDCl 3 ): 3.88(s, 3H); 4.00(br.s, 2H); 6.73-6.82(m, 2H); 7.13-7....

Embodiment C

[0227] Preparation of 4', 5'-dimethoxy-2'-nitrobiphenyl-3-formyl chloride (95)

[0228] Scheme 13

[0229]

[0230] Step 1: DK006 (the following reactions were carried out under nitrogen atmosphere) Tetrakis(triphenylphosphine)-palladium(0) (200mg, 0.17mmol) and methyl 3-bromobenzoate (91) (1.25mg, 5.81mmol ) was dissolved in DME (12 mL), the reaction mixture was carefully degassed (5 times) and washed with N 2 Purge, add 3,4-dimethoxyphenylboronic acid (1.25 g, 6.85 mmol) and 1M NaHCO 3 aqueous solution (17.7 mL, 17.7 mmol), again the reaction mixture was carefully degassed (5 times) and washed with N 2 After purging, the mixture was stirred at 95 °C for 2 hours, the reaction solution was partitioned between EtOAc and water, and the separated aqueous layer was extracted with EtOAc (4 times). The combined organic layers were washed with brine and washed with Na 2 SO 4 After drying, the crude product was purified by flash chromatography (silica gel, CyH / EtOAc 5+1] to af...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Pharmaceutical compositions comprising at least one compound of the formulas (Ia) (Ib) (Ic) (Id) (Ie) (If) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning -X- is e.g. or or or and Y being or or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formulas (Ia) (Ib) (Ic) (Id) (Ie) (If) .The compounds are applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Description

technical field [0001] The present invention relates to compounds, compositions and methods for modulating in vitro and in vivo processes mediated by cell adhesion molecules. The small molecular compounds disclosed in the present invention are aromatic nitro compounds, which potently regulate the activities mediated by cell adhesion molecules. Background technique [0002] Cell adhesion molecule-mediated activities belong to a complex cascade that causes circulating leukocytes (leukocytes) to move from the bloodstream into surrounding tissues (migration). Physiologically, leukocyte migration is crucial to the homeostasis and immune monitoring of organisms (including humans). For example, lymphocytes constitutively leave the bloodstream and enter lymphoid tissues to patrol for harmful antigens. However, under pathological conditions, e.g., local or systemic inflammation and / or vascular system damage, this fundamental process is dysregulated, at least in part, by increased E...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/167A61K31/191A61K31/341A61K31/381A61K31/4418A61K31/4436A61K31/505A61K31/5377A61P1/00A61P11/00A61P17/00A61P17/06A61P29/00A61P43/00C07D213/30
CPCC07C235/34C07D307/68A61K31/381C07D409/12C07D213/75A61K31/5377A61K31/191A61K31/4418C07D409/04C07D333/24C07C235/38A61K31/4436C07D239/20A61K31/505A61K31/167A61K31/341C07D213/40C07D213/30A61P1/00A61P1/04A61P11/00A61P11/06A61P17/00A61P17/06A61P19/02A61P25/00A61P29/00A61P31/00A61P31/04A61P37/00A61P37/02A61P37/08A61P43/00A61P9/00A61P9/08A61P9/10
Inventor 埃瓦尔德·艾德特雷莫·克拉尼奇
Owner REVOTAR BIOPHARMACEUTICALS AG
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More